Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Q32 Bio Inc.

QTTB ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$11.10

▲ +3.54%

Market Cap $330.44M · Vol 269.90K

Key Metrics

P/E Ratio

3.71

FWD: N/A

Market Cap

$330.44M

Small Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

-162.31%

YoY

RSI (14)

12.01

Momentum

Beta

0.31

vs Market

52W High

$23.50

52.77% below

52W Low

$1.70

552.94% above

Volume

269.90K

Avg 127.03K

P/B

1.02

Price-to-book

ROE

N/A

Return on equity

Free Float

81.04%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Q32 Bio Inc. (QTTB) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does QTTB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-13.28%

-27.97%

-12.60%

+60.64%

YTD

+234.34%

+490.43%

-47.29%

-91.91%

Financials & Valuation

TTM · Annual

Total Revenue	$53.74M
Net Income	$29.82M
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	31.45%
Net Profit Margin	55.49%
ROE	N/A
ROA · ROIC	38.70% · 88.28%

P/E Ratio	3.71
Forward P/E (FY1)	N/A
PEG Ratio	0.01
P/S	0.76
P/B	1.02
P/FCF	N/A
EPS Growth	-162.31%
Outstanding Shares	29.77M

Technical Indicators

50-Day SMA	$14.88
200-Day SMA	$8.22
RSI (14)	12.01
Beta	0.31
52-Week High	$23.50
52-Week Low	$1.70

Volume Today	269.90K
Avg Daily Volume (30D)	127.03K
Relative Volume	2.12x
Volatility (10D)	47.41
Volatility (30D)	52.83
Free Float	81.04%

Analyst Consensus

BUY

Current Price $11.10

Mean Target $41.00

52W Low$1.70 52W High$23.50

Current

Target

$1.70 $23.50

Current Analyst target

+269.37% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00CTTJWS7

ISINUS7469641051

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeUNT Unit

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -1.15% ARGX.BR argenx SE -0.23% ARGX argenx SE +0.04% INSM Insmed Incorporated +1.67% 2269.HK WuXi Biologics (Cayman) Inc. -1.05%

Company Profile

Q32 Bio Inc. is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb – CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.